GILEAD SCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
GILD$169.32+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (in millions, except per share amounts) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $7,564 | $9,991 |
| Short-term marketable debt securities | 68 | — |
| Accounts receivable, net | 4,913 | 4,420 |
| Inventories | 1,774 | 1,710 |
| Prepaid and other current assets | 4,024 | 3,052 |
| Total current assets | 18,342 | 19,173 |
| Property, plant and equipment, net | 5,606 | 5,414 |
| Long-term marketable debt securities | 2,974 | — |
| Intangible assets, net | 16,978 | 19,948 |
| Goodwill | 8,314 | 8,314 |
| Deferred tax assets | 1,964 | 2,378 |
| Other long-term assets | 4,845 | 3,769 |
| Total assets | $59,023 | $58,995 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $715 | $833 |
| Accrued rebates | 4,337 | 3,892 |
| Current portion of long-term debt, net | 2,807 | 1,815 |
| Other current liabilities | 3,953 | 5,464 |
| Total current liabilities | 11,813 | 12,004 |
| Long-term debt, net | 22,129 | 24,896 |
| Long-term income taxes payable | 896 | 830 |
| Deferred tax liabilities | 402 | 724 |
| Other long-term liabilities | 1,165 | 1,295 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | — | — |
| Common stock, par value $0.001 per share; 5,600 authorized; 1,241 and 1,246 shares issued and outstanding, respectively | 1 | 1 |
| Additional paid-in capital | 8,932 | 7,700 |
| Accumulated other comprehensive income | 39 | 132 |
| Retained earnings | 13,730 | 11,497 |
| Total Gilead stockholders’ equity | 22,703 | 19,330 |
| Noncontrolling interest | (84) | (84) |
| Total stockholders’ equity | 22,618 | 19,246 |
| Total liabilities and stockholders’ equity | $59,023 | $58,995 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.